Expert Opinion on Drug Safety Launches an Open-Access Correspondence Section

LONDON, January 6 /PRNewswire/ -- Since the withdrawal of Vioxx, issues surrounding drug safety, adverse events and pharmacovigilance have become more important than ever, leading to a plethora of debate and discussion regarding drug safety issues. The fine balance between benefit and risk means that there are many differing opinions from experts spanning different disciplines including pharmacology, clinical medicine, pharmacoeconomics and regulatory affairs. Over the last year, Expert Opinion on Drug Safety has seen an increase in the amount of feedback received. To accommodate this, the journal has launched a correspondence section, in which readers can address issues arising from reviews published in the journal. This correspondence section also allows the author to reply, thus stimulating interesting debate - an important forum for discussion.
According to Dr John Barrett, Senior Director - Infectious Diseases, Merck Research Laboratories, "Expanding the journal with the addition of a correspondence section has enhanced the journal's impact by providing for lively and timely exchange of opinion."
All letters published in the correspondence section are freely available online at www.ashley-pub.com/eds.
Published six times a year, Expert Opinion on Drug Safety seeks to unravel the vast amount of drug safety information and provide clear and informed guides. Each article contains an 'Expert Opinion' section, in which authors are encouraged to express their personal opinion on the status of the research under review.
About Expert Opinion
For over a decade, the Expert Opinion series has provided systematic and authoritative reviews to support every stage of the drug discovery and R&D pipeline from target to market. Each of the nine journals in the series covers a specific aspect of the pharmaceutical pipeline.
The series contains the following journals: Expert Opinion on Biological Therapy, Expert Opinion on Drug Metabolism & Toxicology, Expert Opinion on Drug Safety, Expert Opinion on Emerging Drugs, Expert Opinion on Investigational Drugs, Expert Opinion on Pharmacotherapy, Expert Opinion on Therapeutic Patents, and Expert Opinion on Therapeutic Targets.
New for June 2006 - Expert Opinion on Drug Discovery
This new addition to the Expert Opinion range will focus on drug discovery in the post-genomic era, with particular emphasis on the technologies and disciplines involved; assay development, modelling, in silico drug design and informatics.